CST, 16812S, Bavdegalutamide (ARV-110)

Product Usage Information
Bavdegalutamide (ARV-110) is supplied as a lyophilized powder. For a 5 mM stock, reconstitute 5 mg of powder in 1.23 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles .
Background
Bavdegalutamide (ARV-110) is an androgen receptor (AR) proteolysis targeting chimeric (PROTAC) degrader being studied for prostate cancer treatment (1). AR signaling plays a pivotal role in the development of prostate cancer, and while current therapies already target AR signaling, AR alterations can occur as prostate cancer progresses. These alterations can become resistant to traditional therapies, which are predominantly used to block the AR (1,2). Bavdegalutamide (ARV-110) operates differently by promoting AR protein ubiquitination and degradation and has been known to inhibit cellular growth in VCaP (IC = 1.5 nM) and LNCaP (IC = 16.2 nM) cell lines (2). Bavdegalutamide (ARV-110) binds to the AR and then recruits an E3 ubiquitin ligase to tag the AR for degradation (1). Bavdegalutamide (ARV-110) is also currently being used in clinical trials to investigate its effects in patients with metastatic castration-resistant prostate cancer (1).